The UK’s Medicines and Healthcare Products Regulatory Authority (MHRA) has approved a trial investigating psilocin for major depressive disorder (MDD) that will be carried out in...
PSYCH Symposium is returning at the British Museum on 6 July, when a panel of changemakers and MEPs will discuss the future of psychedelic healthcare in...
New findings from an animal study show that psychedelics open a ‘critical period’ of social reward learning in the brain, but that different psychedelics do so...
COMPASS Pathways and MAPS Public Benefit Corporation (PBC) have put forward a joint application for a new code to facilitate access to psychedelic therapies in the...
Global investment firm Psych Capital has agreed to acquire 100% of the issued share capital of Shortwave Pharma Inc.,
Eleven major neuroscientific research projects related to “The Science of Perception Box” are being funded by the Tiny Blue Dot Foundation, each project receiving three consecutive...
Psilera, a biopharmaceutical company developing next-generation mental health treatments for take-home use, announces the selection of their lead clinical candidate, PSIL-006.
A new report estimates that more than four million people in the Americas, Europe, Australia, and New Zealand have consumed ayahuasca at some point in their...
A study has provided new insights into how psychedelics promote plasticity in the brain – suggesting that the antidepressant effects and the hallucinatory effects may have...
Timmy Davis of the Conservative Drug Policy Reform Group (CDPRG) tells Psychedelic Health about the organisation’s campaign to reschedule psilocybin in a bid to increase psychedelic...